[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053738":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":19,"locations":25,"responsibleParty":38,"collaborators":10,"id":40,"slug":10,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":41,"sex":47,"minAge":48,"maxAge":10,"enrollmentInfo":49,"targetDuration":10,"studyType":52,"phases":10,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Ribociclib arm",null,"Patient treated with ribociclib and Endocrine Therapy (ET) per standard of care",{"label":13,"type":10,"description":14,"interventionNames":10},"Abemaciclib arm","Patient treated with abemaciclib and Endocrine Therapy (ET) per standard of care",[16],{"name":17,"affiliation":17,"role":18},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[20,24],{"name":17,"role":21,"phone":22,"phoneExt":10,"email":23},"CONTACT","+41613241111","novartis.email@novartis.com",{"name":17,"role":21,"phone":10,"phoneExt":10,"email":10},[26],{"facility":27,"status":28,"city":29,"state":10,"zip":30,"country":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":10},"Novartis Investigative Site","RECRUITING","London","SW3 6JJ","United Kingdom",{"type":33,"coordinates":34},"Point",[35,36],-0.12574,51.50853,{"lat":36,"lon":35},{"type":39,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100053738",false,"NCT07243002","Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.","Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters: A Hybrid Study With Prospective Patient-reported Outcomes and Retrospective Clinical Chart Review.","REPOWER","Inclusion Criteria:\n\n* Males or females.\n* Diagnosed with breast cancer, as defined by the International Classification of Diseases (ICD), 9th or 10th Revision, Clinical Modification (ICD-9-CM 174.xx, 175.xx\u002FICD-10-CMC50.xx).\n* Aged ≥18 years (or local legal age of consent) at the date of initial breast cancer diagnosis.\n* Patients with anatomic staging II and III as determined using American Joint Committee on Cancer (AJCC) Criteria.\n* Have initiated adjuvant therapy with ribociclib or abemaciclib, per the approved local label, in combination with ET (within 14 days prior to enrollment).\n* Have HR+ status, as determined by the closest biomarker test on or before the adjuvant therapy initiation date:\n\n  * Tested positive for estrogen receptor (ER+), or\n  * Tested positive for progesterone receptor (PR+), or\n  * Tested positive for both.\n* Tested negative for HER2 (HER2-) using the closest biomarker test on or before the adjuvant therapy initiation date.\n\nExclusion Criteria:\n\n* Patients with local or distant breast cancer recurrence before the ribociclib\u002Fabemaciclib initiation date.\n* Patients enrolled in clinical trials (receiving treatment with clinical study drugs in any setting, i.e., neoadjuvant, adjuvant, local\u002Fregional, metastatic) during the 12-month baseline period.\n* Patients physically\u002Fmentally incapable of understanding the study requirements or fulfilling data collection instruments and require the support of a legally authorized representative.","ALL","18 Years",{"count":50,"type":51},3000,"ESTIMATED","OBSERVATIONAL","This non-interventional study (NIS) aims to evaluate effectiveness, persistence, treatment patterns, adverse events (AEs), and patient-reported experience (including adherence, treatment satisfaction, health-related quality of life \\[HRQoL\\], work productivity, and etc.), among HR+\u002FHER2- stage II and III eBC patients treated with ribociclib + ET, and to evaluate AEs and patients-reported experience among HR+\u002FHER2- stage II and III eBC patients treated with abemaciclib + ET, as per local label.",[55],"Breast Cancer",[57,55,58],"ribociclib, abemacicblib","Non interventional study","2026-07-09",{"date":61,"type":62},"2026-07-13","ACTUAL",{"date":64,"type":62},"2025-12-15",{"date":66,"type":51},"2030-04-30",{"name":17,"class":6},1]